Resolution of sleepiness and fatigue: a comparison of bupropion and selective serotonin reuptake inhibitors in subjects with major depressive disorder achieving remission at doses approved in the European Union

Journal of Psychopharmacology
James A CooperGeorge I Papakostas

Abstract

Unlike selective serotonin reuptake inhibitors (SSRIs), bupropion may be classified as a dual noradrenaline and dopamine reuptake inhibitor, a difference with potential implications for the treatment of residual sleepiness and fatigue in major depressive disorder (MDD). Post-hoc analysis of subjects with remitted MDD was performed on data pooled from six double-blind, randomized trials comparing the European Union (EU)-approved dose of ≤300 mg/day bupropion with SSRIs (sertraline, paroxetine or escitalopram) for the resolution of sleepiness and fatigue. Hypersomnia score was defined as the sum of scores of the Hamilton Depression Rating Scale (HDRS) items 22, 23, and 24; fatigue score as HDRS item 13 score; and remission as HDRS-17≤7. Similar proportions of bupropion- and SSRI-treated subjects achieved remission at study endpoint (169/343, 49.3% vs 324/656, 49.4%; last observation carried forward (LOCF), p=0.45). Fewer bupropion-treated remitters had residual symptoms of sleepiness (32/169, 18.9% vs 104/324, 32.1%; p<0.01) and fatigue (33/169, 19.5% vs 98/324, 30.2%; p<0.05). Bupropion-treated remitters also showed greater improvement (mean change from baseline) in sleepiness (p<0.05) and fatigue scores (p<0.01) at endpoint: be...Continue Reading

References

Oct 1, 1992·Journal of Affective Disorders·E HorwathC D Hornig
Jul 1, 1971·Comprehensive Psychiatry·M BakerR J Cadoret
Nov 1, 1995·Psychological Medicine·E S PaykelA Barocka
Feb 4, 1998·The Journal of Clinical Psychiatry·R J KavoussiJ A Johnston
Apr 30, 1999·The Journal of Clinical Psychiatry·A A NierenbergM Fava
Apr 18, 2000·Archives of General Psychiatry·L L JuddM B Keller
May 19, 2000·The Journal of Clinical Psychiatry·K L WeihsJ A Ascher
Nov 17, 2001·Psychiatry Research·M A Posternak, M Zimmerman
Mar 12, 2004·Primary Care Companion to the Journal of Clinical Psychiatry·James M. Ferguson
Oct 16, 2004·The International Journal of Neuropsychopharmacology·Koen DemyttenaereStephen M Stahl
Jul 20, 2005·Primary Care Companion to the Journal of Clinical Psychiatry·Maurizio FavaJ Andrew Johnston
Apr 25, 2006·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Sidney H KennedyShahryar Rafi-Tari
Nov 4, 2006·The Journal of Clinical Psychiatry·L Fredrik Jarskog, Jeffrey A Lieberman
Aug 23, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Michael J Minzenberg, Cameron S Carter
Aug 31, 2007·Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists·Maurizio FavaRod J Hughes
Nov 8, 2007·Journal of Psychiatric Research·Mark ZimmermanNaureen Attiullah
Mar 28, 2008·The Journal of Clinical Psychiatry·Madhukar H TrivediPierre Blier
Feb 1, 2007·Neuropsychiatric Disease and Treatment·George I PapakostasJonathan E Alpert
Jul 11, 2009·Expert Review of Neurotherapeutics·Benji T KurianMadhukar H Trivedi
Apr 22, 2010·CNS Neuroscience & Therapeutics·Mostafa El MansariPierre Blier
Feb 22, 2012·Expert Opinion on Emerging Drugs·Kevin Ryan Connolly, Michael E Thase

❮ Previous
Next ❯

Citations

Jun 25, 2015·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Samantha E YohnJohn D Salamone
Aug 11, 2015·Current Sleep Medicine Reports·David T Plante
May 18, 2016·Brain : a Journal of Neurology·John D SalamoneMercè Correa
Jun 15, 2016·Pharmacology, Biochemistry, and Behavior·Samantha E YohnJohn D Salamone
Oct 16, 2014·Journal of Psychopharmacology·Roger M Lane
Sep 27, 2014·Multiple Sclerosis : Clinical and Laboratory Research·Katrin HankenHelmut Hildebrandt
Jan 9, 2020·Journal of Psychopharmacology·Martin A KatzmanMatthieu Boucher
Jan 9, 2020·Journal of Psychopharmacology·Mason M SilveiraCatharine A Winstanley
Apr 10, 2018·Frontiers in Behavioral Neuroscience·John D SalamoneRose Presby
Dec 5, 2020·European Archives of Psychiatry and Clinical Neuroscience·Galina SurovaUlrich Hegerl
May 7, 2021·The Psychiatric Quarterly·Sevlin BozMatthieu Hein

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.